Epigenome-wide discovery of ovarian and breast cancer specific DNA methylation markers

Hitomi Hasegawa\(^1\)  
hitomi.hasegawa@genedata.com

Harri Lempiäinen\(^1\)  
harri.lempiainen@genedata.com

Dominik Mertens\(^1\)  
dominik.mertens@genedata.com

Arnd Brandenburg\(^1\)  
arnd.brandenburg@genedata.com

Andreas Biegertirst\(^1\)  
andreas.biegert@genedata.com

Michael Remmerte\(^1\)  
michael.remmert@genedata.com

Jane Hayward\(^2\)  
jane.hayward.09@ucl.ac.uk

Allison Jones\(^2\)  
allison.jones@ucl.ac.uk

Shahzia Anjum\(^2\)  
s.anjum@ucl.ac.uk

Martin Widschwendter\(^2\)  
m.widschwendter@ucl.ac.uk

Marc Flesch\(^1\)  
marc.flesch@genedata.com

Jens Hoefkens\(^1\)  
jens.hoefkens@genedata.com

Tamas Rujan\(^1\)  
tamas.rujan@genedata.com

Timo Wittenberger\(^1\)  
timo.wittenberger@genedata.com

\(^1\) Genedata AG Margarethenstrasse 38, 4053 Basel, Switzerland  
\(^2\) Department of Women’s Cancer, University College London, Elizabeth Garrett Anderson Institute for Women’s Health, London, UK

Keywords: Next Gene Sequencing, Omics data, DNA Methylation, Epigenomics, Clinical Bioinformatics

Breast and ovarian cancers pose huge and unsolved challenges to the medical profession. The EU FP7 consortium EpiFemCare develops blood tests based upon DNA methylation technology to facilitate early detection and prediction of therapeutic outcome of these cancers. In phase 1 of the project Infinium® HumanMethylation450 BeadChip technology is used to assess the methylation status of ~485’000 sites in cancer and control tissues. In parallel, Reduced Representation Bisulfite Sequencing (RRBS) is used to identify and confirm cancer specific methylated circulating DNA in matching serum samples. Using Genedata Expressionist® for Genomic Profiling, we have established an automated bioinformatics pipeline for the detection of cancer specific Differentially Methylated Regions (DMRs) that most likely fulfill the strict specificity criteria of a serum based test. The most promising DMRs are taken forward to clinical assay development (phase 2) and validation in thousands of serial samples from prospective clinical trials (phase 3).